Strategy

Aug 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Aug 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Planning for the long term is increasingly seen as an abstract absurdity. But a lasting business model is still possible—if you learn to adapt.
Aug 01, 2012
Pharmaceutical Executive
Creative non-pharmaceutical partnerships can offer innovators unique capabilities against the competition in a new era where challenges to market leadership are coming from every direction.
Aug 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020—just watch out for the harsh light of complacency.
Jul 01, 2012
Pharmaceutical Executive
In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises—change for pharma is here and its good.
Jul 01, 2012
Pharmaceutical Executive
Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded—and lengthy—race to registration.
Jun 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
No matter how the Supreme Court rules on healthcare reform, the accountable care model will stick around. To play ball with ACOs, drug companies will need to throw a different pitch.
Jun 01, 2012
Pharmaceutical Executive
Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead.
Jun 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
As brands are required to produce more and more data to convince not only regulators, but payers, physicians, and patients, Jeffrey Jonas is pushing Shire's "search and develop" R&D model into new and sometimes uncomfortable territory.
May 01, 2012
Pharmaceutical Executive
Will changes to the P&R system in the UK finally put some real metrics behind the elusive concept of value?
native1_300x100
lorem ipsum